6 results about "Cyclononane" patented technology

The invention discloses a catalyst for preparing ultrahigh molecular weight polyoxyethylene as well as a preparation method and application thereof, and relates to the technical field of catalyst preparation. The preparation method of the catalyst comprises the following steps: S1, carrying out a reaction on 6-hexamethylenediamine and allyl acrylate to generate an intermediate 1, S2, carrying out a reaction on the intermediate 1 and diphenylphosphine to generate an intermediate 2, S3, carrying out a reaction on the intermediate 2 and allyl bromide to generate an intermediate 3, and S4, carrying out a reaction on the intermediate 3 and 9-boron bicyclo [3.3. 1] nonane. The prepared catalyst is high in catalytic activity, ultrahigh molecular weight polyoxyethylene can be prepared, and the molecular weight distribution of the prepared ultrahigh molecular weight polyoxyethylene is narrow.

The present invention is related to a compound of formula (I):whereinR1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl;AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid;R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl;ALK is (C2-C5)alkylidene;R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (II)whereinALK′ is (C2-C5)alkylidene;R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; andR7 is selected from the group consisting of H and an Effector moiety;or a pharmacologically acceptable salt, solvate or hydrate thereof.

A combination of the present invention is an effective therapy for glaucoma, in particular a combination of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate and a β-blocker, is useful as an agent for treating glaucoma since the combination enhances intraocular pressure lowering action compared to a single administration of each drug and has an effect of maintaining intraocular pressure lowering action.

The present invention relates to a crystalline form of the compound (22R,24S,5S)-24,35-difluoro -5-methyl-4-oxa-7,9-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidin-3(3,2)-pyridin-2(1,2) -pyrrolidincyclononuan-8-one of formula (I) and a preparation method therefor. The crystalline form provided in the present invention has favorable properties in terms of stability and hygroscopicity, and is suitable for drug research and industrial production. The crystalline form has significant value for the optimization and development of the drug in the future.

The invention discloses a green synthesis method of moxifloxacin hydrochloride, which comprises the following steps: under a heating condition, reacting moxifloxacin cyclization ester with moxifloxacin ((S, S)-2, 8-diazabicyclo [4, 3, 0] nonane) in a solvent, alkali and catalyst system to obtain moxifloxacin ester, and then carrying out hydrolysis one-pot method in an acidic system to obtain the moxifloxacin hydrochloride. The moxifloxacin hydrochloride is directly prepared. The invention provides a green synthesis method of moxifloxacin hydrochloride. According to the green synthesis method, moxifloxacin is obtained through direct reaction of moxixane cyclization ester and moxixane. According to the method, the moxifloxacin serving as a target product is synthesized by taking the moxixane cyclization ester as a raw material without forming a chelate compound with boric acid ester and directly reacting with the moxixane through a one-pot method, no three wastes are generated in the preparation process, and the method has the advantages of short reaction steps, mild conditions, high yield and the like.